EI

281.9

+0.64%↑

SAN

85.92

+0.86%↑

MRK1

118.7

-1.08%↓

SHL.DE

47.14

+1.84%↑

UCB

248.6

+1.14%↑

EI

281.9

+0.64%↑

SAN

85.92

+0.86%↑

MRK1

118.7

-1.08%↓

SHL.DE

47.14

+1.84%↑

UCB

248.6

+1.14%↑

EI

281.9

+0.64%↑

SAN

85.92

+0.86%↑

MRK1

118.7

-1.08%↓

SHL.DE

47.14

+1.84%↑

UCB

248.6

+1.14%↑

EI

281.9

+0.64%↑

SAN

85.92

+0.86%↑

MRK1

118.7

-1.08%↓

SHL.DE

47.14

+1.84%↑

UCB

248.6

+1.14%↑

EI

281.9

+0.64%↑

SAN

85.92

+0.86%↑

MRK1

118.7

-1.08%↓

SHL.DE

47.14

+1.84%↑

UCB

248.6

+1.14%↑

Search

Genfit

Cerrado

SectorSanidad

3.49 3.56

Resumen

Variación precio

24h

Actual

Mínimo

3.37

Máximo

3.49

Métricas clave

By Trading Economics

Ingresos

-29M

Ventas

8M

P/B

Media del Sector

104.267

35.739

Margen de beneficios

-358.75

Empleados

188

EBITDA

-24M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+149.22% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

164M

Apertura anterior

-0.07

Cierre anterior

3.49

Noticias sobre sentimiento de mercado

By Acuity

39%

61%

112 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Genfit Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 oct 2025, 23:30 UTC

Acciones populares

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 oct 2025, 21:21 UTC

Ganancias

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 oct 2025, 00:00 UTC

Adquisiciones, fusiones, absorciones

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 oct 2025, 23:40 UTC

Charlas de Mercado

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 oct 2025, 23:39 UTC

Charlas de Mercado

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 oct 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 oct 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 oct 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 oct 2025, 23:00 UTC

Charlas de Mercado

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 oct 2025, 22:54 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Scales's JV Buyout Lauded by Bull -- Market Talk

2 oct 2025, 22:54 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Forex and Fixed Income Roundup: Market Talk

2 oct 2025, 22:46 UTC

Charlas de Mercado

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 oct 2025, 22:46 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 oct 2025, 21:17 UTC

Adquisiciones, fusiones, absorciones

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 oct 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Energy & Utilities Roundup: Market Talk

2 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

2 oct 2025, 20:49 UTC

Adquisiciones, fusiones, absorciones

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 oct 2025, 20:00 UTC

Adquisiciones, fusiones, absorciones

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 oct 2025, 19:20 UTC

Charlas de Mercado

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 oct 2025, 19:10 UTC

Charlas de Mercado

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 oct 2025, 19:04 UTC

Charlas de Mercado

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 oct 2025, 18:45 UTC

Adquisiciones, fusiones, absorciones

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 oct 2025, 18:45 UTC

Adquisiciones, fusiones, absorciones

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 oct 2025, 18:44 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 oct 2025, 18:44 UTC

Adquisiciones, fusiones, absorciones

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 oct 2025, 18:44 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 oct 2025, 18:43 UTC

Adquisiciones, fusiones, absorciones

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Comparación entre iguales

Cambio de precio

Genfit previsión

Precio Objetivo

By TipRanks

149.22% repunte

Estimación a 12 Meses

Media 8.399 EUR  149.22%

Máximo 8.4 EUR

Mínimo 8.4 EUR

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Genfit Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

1

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

3.566 / 4.12Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

112 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
help-icon Live chat